{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T04:40:15Z","timestamp":1762144815695,"version":"3.38.0"},"reference-count":43,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2011,9,6]],"date-time":"2011-09-06T00:00:00Z","timestamp":1315267200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Basic Clin Pharma Tox"],"published-print":{"date-parts":[[2012,2]]},"abstract":"<jats:p><jats:bold>Abstract:\u2002<\/jats:bold>The effects of the K<jats:sub>v<\/jats:sub>7 channel modulators retigabine (opener) and XE991 (blocker) on rat bladder function were investigated<jats:italic>ex vivo<\/jats:italic>and<jats:italic>in vivo<\/jats:italic>to assess the potential of K<jats:sub>v<\/jats:sub>7 openers for the treatment of overactive bladder. In organ bath studies, capsaicin\u2010stimulated rat urinary bladder rings were exposed to retigabine and XE991 and the effect on tension and amplitude was evaluated. In anaesthetized rats, retigabine (0.01\u20131\u2003mg\/kg, i.v.) effects on bladder function, in which overactivity was induced by continuous infusion of 0.5% acetic acid, were assessed. The effect of retigabine (10\u2003mg\/kg, p.o.) on cystometric parameters was also measured in conscious rats with capsaicin\u2010induced irritated bladders. Localization of K<jats:sub>v<\/jats:sub>7 subunits within bladder tissue was analysed by RT\u2010qPCR and western blotting. In organ bath studies, retigabine robustly reduced capsaicin\u2010induced contractility of bladder rings and this effect was blocked by XE991 confirming the specificity of action<jats:italic>via<\/jats:italic>K<jats:sub>v<\/jats:sub>7 channels. In anaesthetized rats with acetic acid\u2013irritated bladders, retigabine markedly increased bladder capacity with no concomitant reduction in blood pressure. Retigabine also reduced bladder pressure and delayed voiding in conscious rats with capsaicin\u2010irritated bladders. K<jats:sub>v<\/jats:sub>7.1, K<jats:sub>v<\/jats:sub>7.4 and K<jats:sub>v<\/jats:sub>7.5 subunit mRNA transcripts were detected in rat bladder. Western blot analysis confirmed that K<jats:sub>v<\/jats:sub>7.4 subunit protein was expressed in rat bladder. These results suggest that retigabine and other K<jats:sub>v<\/jats:sub>7 channel positive modulators may have beneficial effects on bladder overactivity partly<jats:italic>via<\/jats:italic>activation of K<jats:sub>v<\/jats:sub>7 channels expressed in bladder tissue.<\/jats:p>","DOI":"10.1111\/j.1742-7843.2011.00765.x","type":"journal-article","created":{"date-parts":[[2011,9,6]],"date-time":"2011-09-06T09:18:33Z","timestamp":1315300713000},"page":"145-153","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["K<sub>v<\/sub>7 Positive Modulators Reduce Detrusor Overactivity and Increase Bladder Capacity in Rats"],"prefix":"10.1111","volume":"110","author":[{"given":"Julie","family":"Sval\u00f8","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henrik H.","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lars Christian B.","family":"R\u00f8nn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Majid","family":"Sheykhzade","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gordon","family":"Munro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frederik","family":"Rode","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2011,9,6]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2006.09.019"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrn2401"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1097\/MOU.0b013e3281299033"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1002\/nau.20500"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.16.7.999"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1097\/00029330-200808020-00014"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11884-009-0018-y"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0163-7258(01)00116-4"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1186\/1465-9921-7-31"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1582-4934.2010.01021.x"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.0128-05.2005"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.21-15-05535.2001"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1124\/mol.104.010793"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.ju.0000138155.33749.f4"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2009.02.108"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2010.03.050"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.108.143123"},{"key":"e_1_2_6_19_2","first-page":"R115","article-title":"Blockade of voltage\u2010sensitive K(+) channels increases contractility more in transverse than in longitudinal rat detrusor Strips","volume":"10","author":"Ning Lo W","year":"2008","journal-title":"Urology"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1002\/nau.20903"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(01)66660-6"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1152\/jn.2001.86.5.2276"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.2220\/biomedres.30.107"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(05)65936-8"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.autneu.2010.02.006"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00210-006-0073-2"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2003.04722.x"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1038\/bjp.2008.231"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0706342"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1113\/jphysiol.2007.148304"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajpgi.00200.2001"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajpheart.00065.2006"},{"key":"e_1_2_6_33_2","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.107.135764"},{"key":"e_1_2_6_34_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0707284"},{"key":"e_1_2_6_35_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.2010.01027.x"},{"key":"e_1_2_6_36_2","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.108.147785"},{"key":"e_1_2_6_37_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00424-008-0567-5"},{"key":"e_1_2_6_38_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajpgi.00057.2009"},{"key":"e_1_2_6_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(00)80556-5"},{"key":"e_1_2_6_40_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M805216200"},{"key":"e_1_2_6_41_2","unstructured":"Valeant Pharmaceuticals North America.Ezogabine for Partial Seizures in Epilepsy (NDA \u2013 022345) [Internet]. [cited 2011]. Available from:http:\/\/www.fda.gov\/downloads\/AdvisoryCommittees\/CommitteesMeetingMaterials\/Drugs\/PeripheralandCentralNervousSystemDrugsAdvisoryCommittee\/UCM221682.pdf.2010(last accessed on 3 January 2011)."},{"key":"e_1_2_6_42_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2008.09.005"},{"key":"e_1_2_6_43_2","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/S0090-9556(24)15257-9","article-title":"Retigabine N\u2010glucuronidation and its potential role in enterohepatic circulation","volume":"27","author":"Hiller A","year":"1999","journal-title":"Drug Metab Dispos"},{"key":"e_1_2_6_44_2","doi-asserted-by":"publisher","DOI":"10.1124\/mol.108.049825"}],"container-title":["Basic &amp; Clinical Pharmacology &amp; Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1742-7843.2011.00765.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1742-7843.2011.00765.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,9]],"date-time":"2025-03-09T19:16:46Z","timestamp":1741547806000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1742-7843.2011.00765.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,9,6]]},"references-count":43,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,2]]}},"alternative-id":["10.1111\/j.1742-7843.2011.00765.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1742-7843.2011.00765.x","archive":["Portico"],"relation":{},"ISSN":["1742-7835","1742-7843"],"issn-type":[{"type":"print","value":"1742-7835"},{"type":"electronic","value":"1742-7843"}],"subject":[],"published":{"date-parts":[[2011,9,6]]},"assertion":[{"value":"2011-09-06","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}